Six patients with HBV-related cirrhosis, viral breakthrough during LMV therapy and viral breakthrough or non-response during ADV therapy were treated daily with TDF plus LMV for at least 6 months. The HBV DNA level
, alanine aminotransferase (ALT), the Child-Pugh score and serum
creatinine were monitored. Genotypic LMV- or ADV-resistant mutations were measured in stored samples.
3. Results: In five of six patients, ADV-resistant mutations at rt181 or rt236 were detected during ADV therapy.